 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
20188 News |  |
| «12...167168169170171172173174175176177...208209» |
- Taltz (ixekizumab) / Eli Lilly, Humira (adalimumab) / Eisai, AbbVie
Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results (B211-B212) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1811;
P4
Both biologics significantly improved HRQoL and other PROs. Greater improvements in PROs related to PsO were observed for IXE- compared to ADA-treated patients.
- Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients (B405/B407) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1797;
The randomized VERVE trial comprised of more than 600 patients receiving TNFi for multiple indications observed no cases of vaccine-related varicella infection or reactivation in the 6-week risk period following live zoster vaccination. This trial informs safety concerns of use of live virus vaccines in this population.
- Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1758;
Concomitant csDMARDs had a significant positive effect on bDMARDs DRR. Table 1 Taka Figure 1 Taka
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / Eisai, AbbVie
Vascular Damage Is Less Present in an Early Inception Cohort in Takayasu's Arteritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1747;
Our results suggest that, in an inception cohort, signs and symptoms of ‘systemic inflammation’ is more prominent in newly-diagnosed TAK patients, whereas vascular extent and damage accumulates during the disease course. The long term follow-up of our inception cohort shows that 40% of patients relapse within 2 years after diagnosis in spite of IS treatments.
- Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1744;
Patients with RA receiving csDMARDs or TNF blockers demonstrated a constitutively increased frequency of cTfh cells and an overrepresentation of cTfh subsets bearing a B cell helper phenotype, suggesting that altered germinal center dynamics play a role in RA pathogenesis. Remarkably, in RA patients treated with abatacept these frequencies and ratio were not altered, indicating that costimulation blockade is able to revert the increased generation of Tfh cells in RA; conversely, TNF neutralization does not seem to affect the generation or recirculation of cTfh.
- Humira (adalimumab) / Eisai, AbbVie
Low Frequency of Circulating T Follicular Helper 1 Cells Is Associated to Adequate Response to Adalimumab Therapy in Rheumatoid Arthritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1717;
Further analysis of these patients is necessary to understand the relationship between cTfh cells, the cTfh1/cTfh2 balance, B cells activation and antibodies production. Figure 1 Percentage of cTfh1 cells in RA patients and HC at baseline (M0) Figure 2 Positive correlation between the percentage of cTfh PD1+ cells and disease activity at baseline (M0) Figure 3 Percentage of cTfh1 cells 3 months after Adalimumab treatment initiation (M3) in responder (R) and non-responder (NR) patients
- Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Gender Differences in Comorbidities and Treatment Utilization Among Ankylosing Spondylitis Patients Initiating a Biologic in a Real-World Setting (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1665;
The comorbidity and treatment exposures depict a more complex profile for women vs men, which may be important to consider when determining the best approach to disease management. Further real-world studies on treatment patterns are needed to understand factors leading to poor persistence and how best to optimize treatment.
- Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1650;
TNF inhibitors with short intervals tended to be more frequently tapered in patients with AS. Tapering of TNF inhibitors may also help reduce healthcare costs related to AS.
- BAT1406 (adalimumab biosimilar) - Bio / Thera Solutions, Humira (adalimumab) / Eisai, AbbVie
Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1622;
Tapering of TNF inhibitors may also help reduce healthcare costs related to AS. Our results show that even though assays used to detect drug concentration and ADA titer may be influenced by an individual/endogenous immune profile (previous to drug administration), response to ADL does not seem to be significantly affected by ADA titers or ADL concentration.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
A Biomarker of Type VI Collagen Degradation (C6M) Is Associated with Changes in ASDAS MRI Measures of Inflammation in Patients with Axial Spondyloarthritis During TNF Inhibitor Therapy (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1619;
This indicates that C6M may be a tissue-based marker of disease activity. Table 1 Table 1.
- Xeljanz (tofacitinib) / Pfizer, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1617;
Use of IL-17 blockade could be an effective alternative therapy in AS patients who has high AIF-1 level. CD4+ T cell transcriptome changed toward Th17 by AIF-1 (n=4) AIF-1 increased Th17/Th1 ratio Anti-inflammatory effect or anti-Th17 effect of TNF inhibition may be diminished in the AIF-1 high environment.
- Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1607;
In patients with SpA, long-term treatment of TNF-α inhibitor was associated with increased TC, HDL-C, and TG levels and AI, whereas it presented no effect on LDL-C levels. Increased HDL-C may have beneficial effects, but evaluation of cardiovascular event rates during long-term treatment is needed to further characterize these findings and their possible clinical implications.
- Frequency and Characteristics of Inflammatory Bowel Disease in Spondyloarthritis with Biological Therapy: Study of 270 Patients from the Same Center (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1594;
The most frequent form was CD and it was diagnosed after SpA in 60% of the cases. 6 patients were with BT at the time of IBD onset.
- Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / Eisai, AbbVie
Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1485;
MTX‑naïve pts were randomized to UPA 15 or 30mg QD or MTX monotherapy [SELECT‑EARLY, N=945], while MTX-IR pts were randomized to UPA 15mg QD or adalimumab (ADA) 40 mg eow or placebo (PBO), with continuous background MTX [SELECT‑COMPARE, N=1629]. UPA both as monotherapy, and in combination with background MTX, was effective in inhibiting the progression of structural joint damage through Week 48 in MTX-naïve, and MTX-IR patients, respectively.
- Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Impact of Formulary Change on TNFi Treatment Patterns and Healthcare Utilization Costs in RA Patients (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1471;
Continuing and EGR pts using Other-TNFi incurred higher costs than similar ETN pts. Pts switching away from ETN cost more than pts switching away from Other TNFi medications.
- Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / Eisai, AbbVie
Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1467;
Significantly greater proportions of pts receiving UPA 15 or 30mg achieved REM by multiple definitions at 12 wks compared to PBO, MTX or ADA. All disease activity components of each REM definition were significantly improved in pts receiving UPA compared to MTX or PBO, and all Boolean components were significantly improved in pts receiving UPA 15mg compared to ADA.
- Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / Eisai, AbbVie
Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1465;
Inhibition of structural joint damage with UPA was also maintained through 48 wks vs PBO. Safety was consistent with observations in the first 26 wks.1
- Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / Eisai, AbbVie
The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1461;
In MTX-naïve and MTX-IR pts, treatment responses at 12 wks occurred in significantly higher proportions of pts receiving UPA monotherapy vs MTX and UPA + MTX vs PBO for all 7 components of the ACR response criteria, and for 5 of 7 ACR components for UPA + MTX vs ADA + MTX. Favorable outcomes with UPA treatment were evident both in composite and individual parameters
- Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / Eisai, AbbVie
Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1447;
The rate of HZ was higher on both UPA doses compared to MTX and ADA. The rates of VTE, MACE, and malignancy were comparable with that observed in the MTX and ADA groups while also being consistent with reported rates in the RA population
- Humira (adalimumab) / Eisai, AbbVie, filgotinib (GLPG0634) / Gilead
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1444;
The selective JAK1 inhibitor FIL, at doses of 200mg and 100mg led to significant improvement in signs and symptoms of RA, prevented radiographic progression, and improved physical function compared to PBO, and was well tolerated among patients with RA with prior inadequate response to MTX. Efficacy of FIL 200mg was non-inferior to ADA based on DAS28-CRP ≤3.2.
- mTORC1-phosphorylated CXCR3+memory B Cells and Their Potential as a New Mode of Action of TNF Inhibitors in RA (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1440;
We examined the change of percentage of CXCR3+CD27+CD19+ cells and the level of p-mTORC1 before and at 1 year after treatment with biologics (37 patients, TNF inhibitors (n=19: adalimumab:11, certolizumab:7, etanercept:1), abatacept (n=16), tocilizumab (n=2))...Combined stimulation of BCR, CD40L and IFN-γ induced CXCR3 expression on B cells, which were abrogated by mTORC1 inhibitors, Rapamycin... Taken together, activation of mTORC1 is involved in the accumulation of CXCR3-positive memory B cells in RA synovium and TNF inhibitors possibly target at this in patients with RA.
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1375;
The subjects were 55 RA patients who filled RA criteria 2010, were treated with adalimumab, certolizumab pegol or golimumab, had serum RF titer ≥45 IU/ml at entry (at starting anti-TNF therapy, month 0), and were followed up until month 12. Continuous decrease in serum RF titer was associated with less progression in mTTS, especially in bone erosion score, of RA patients treated with TNF inhibitors.
- Taltz (ixekizumab) / Eli Lilly, Humira (adalimumab) / Eisai, AbbVie
Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1310;
Improvements in patient-reported HRQoL in A/r-axSpA patients measured with SF-36 were observed at Weeks 4 and 16 and sustained up to 52 weeks of continuous IXE treatment. Figure SF-36 Physical Component Summary Mean Change from Baseline (COAST-V and COAST-W) Table SF-36 Baseline Scores and Mean Change at Week 52
- Xeljanz (tofacitinib) / Pfizer, Humira (adalimumab) / Eisai, AbbVie
Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1302;
P3
Time to initial response prior to first post-BL observation (Week 2 or M1) was not estimable in this analysis. These results may help physicians better understand the time frame for a meaningful response in pts receiving tofacitinib.
- Humira (adalimumab) / Eisai, AbbVie
The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1298;
Statistically significant and clinically meaningful improvements and scores ≥A/G norms (higher definition of response) at week 12 were reported with ADA treatment vs PBO in pts with moderately to severely active PsA. These data are consistent with improvements in PROs reported with other bDMARDs in patients with PsA.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Roche, Biogen
Experience with Biologic Agents for the Treatment of Cardiac Sarcoidosis in a U.S. Academic Medical Center (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1251;
Based on our small cohort, biologics (mainly TNF alpha antagonists) appear to be safe and efficacious as salvage therapy for cardiac sarcoidosis. However, there is a need for prospective studies to further validate these findings as well as to identify the subset of patients that would benefit from early initiation of these therapies.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, tacrolimus / Generic Mfg., Humira (adalimumab) / Eisai, AbbVie
Role of Alternative Immunosuppressant Therapy in Management of Cardiac Sarcoidosis (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1247;
We describe clinical manifestations and treatment outcomes of 14 patients with CS managed with an oral immunosuppressive agent or TNFi with favorable outcomes. Further larger scale prospective studies are required to identify the most appropriate immunosuppressant regimen and conclude its efficacy in management of CS.
- Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In Vitro (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1175;
For each of the conditions tested in vitro, many resembling features associated with RA, the pre-formed complexes of ADA:TNF and CZP:TNF were significantly more effective in preventing the TNF-induced effects (decrease of surface TNF-RI and alpha-2,6 Sia; increase in NF-kB activation, ICAM-1 surface levels and apoptosis) on human monocytes than those complexes of TNF with ETN, IFX or GOL. Additional in vitro and in vivo studies need to be done to further elucidate these mechanistic differences.
- Orencia (abatacept) / BMS, Humira (adalimumab) / Eisai, AbbVie
Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1115;
Although patients are more likely to cycle to a second TNFi than swap, those who swap to a non-TNFi drug are more likely to persist with the second-line therapy. However, cycling appears to be the less costly strategy.
- Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1112;
Abatacept patients also experienced a longer time to discontinuation than the TNFi cohort, which may be explained by the significantly lower proportion of patients discontinuing abatacept due to disease progression. Perhaps due to limited sample size, the adjusted comparison of abatacept and TNFi persistence is not significant, however, numeric trends are consistent.
- |||| Humira (adalimumab) / Eisai, AbbVie
Clinical: @EdwardLoftus2 6 year safety and durability data on Humira in #CD @CrohnsColitisFn https://t.co/sxTtmuNdtN (Twitter) - Oct 4, 2019
- | Humira (adalimumab) / Eisai, AbbVie
Journal: Quantitative assessment of mAb Fc glycosylation of CQA importance by capillary electrophoresis. (Pubmed Central) - Oct 4, 2019
Therefore, if effector function is the main mode of action of a monoclonal antibody therapeutic, microheterogeneity of this Fc glycosylation such as core fucosylation (for antibody-dependent cell-mediated cytotoxicity, ADCC), galactosylation (for complement-dependent cytotoxicity, CDC) and sialylation (for anti-inflammatoryfunction) 5 should be closely monitored in each phase of product development 6. On the other hand, albeit not important for the above listed functions, the presence of high mannose type glycans should be scrutinized as it greatly affects serum half-life via interaction with mannose-binding lectins (MBL) in the liver 7.
- | Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical, Review, Journal: Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature. (Pubmed Central) - Oct 4, 2019
We indicate the immunodysregulatory and proinflammatory effects of etanercept and discuss the potential pathogenic mechanisms of the paradoxical effect of TNF-α inhibitors. We also review the related literature on new-onset IBD following anti-TNF treatment for AS.
- Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
HIGH VERSUS STANDARD ADALIMUMAB INDUCTION DOSING REGIMENS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE SERENE-CD INDUCTION STUDY (B2) - Oct 4, 2019 - Abstract #UEGW2019UEGW_4237;
P3
A clear ERR was observed for endoscopic response. Both dosing regimens were generally safe and well tolerated.
- | Review, Journal: An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis. (Pubmed Central) - Oct 4, 2019
For psoriatic arthritis, all of these drugs are approved in addition to ixekizumab, ustekinumab, abatacept, and tofacitinib. Selection of the optimal bDMARD should consider patient comorbidity including uveitis, psoriasis, and inflammatory bowel disease.
- | Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Journal: Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. (Pubmed Central) - Oct 4, 2019
P3
In this trial involving patients with moderately to severely active ulcerative colitis, vedolizumab was superior to adalimumab with respect to achievement of clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission. (Funded by Takeda; VARSITY ClinicalTrials.gov number, NCT02497469; EudraCT number, 2015-000939-33.).
- | Jyseleca (filgotinib) / Galapagos, Gilead
New P3 trial: PENGUIN 1: Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy (clinicaltrials.gov) - Oct 4, 2019
P3, N=1001, Not yet recruiting, Sponsor: Gilead Sciences
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate (clinicaltrials.gov) - Oct 4, 2019
P=N/A, N=28, Recruiting, Sponsor: University Hospital, Basel, Switzerland
(Funded by Takeda; VARSITY ClinicalTrials.gov number, NCT02497469; EudraCT number, 2015-000939-33.). Not yet recruiting --> Recruiting
- | Enbrel (etanercept) / Pfizer, Amgen
Trial completion date, Trial primary completion date: Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 4, 2019
P3b/4, N=4414, Active, not recruiting, Sponsor: Pfizer
Not yet recruiting --> Recruiting Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Mar 2020 --> Sep 2020
- | Humira (adalimumab) / AbbVie
Trial completion date, Trial primary completion date, HEOR: Rheumatoid Arthritis Satisfaction Outcome Research (clinicaltrials.gov) - Oct 3, 2019
P=N/A, N=840, Recruiting, Sponsor: Pfizer
Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Mar 2020 --> Sep 2020 Trial completion date: Sep 2019 --> Dec 2019 | Trial primary completion date: Sep 2019 --> Dec 2019
- | Actemra IV (tocilizumab) / Roche, JW Pharma
New trial: A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab (clinicaltrials.gov) - Oct 3, 2019
P, N=4540, Not yet recruiting, Sponsor: Sungkyunkwan University
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, tacrolimus / Generic Mfg., Humira (adalimumab) / Eisai, AbbVie
Review, Journal: Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. (Pubmed Central) - Oct 3, 2019
However, immunomodulators such as methotrexate, tacrolimus, azathioprine, cyclosporine and mycophenolate mofetil together with anti-tumor necrosis factor-α (anti-TNF alpha) monoclonal antibodies such as adalimumab and infliximab, may be required to control the inflammation and the associated ME in refractory cases, or when an underlying disease is present. This review of the literature will focus mostly on the non-infectious UME.
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population. (Pubmed Central) - Oct 3, 2019
Participation in the PSP, higher income, and using a specialty pharmacy were associated with lower odds of abandoning ADA therapy, whereas increased copayments were associated with greater abandonment. PSPs should be considered to improve initiation of ADA therapy.
- | Clinical, Journal, Adverse events: Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting. (Pubmed Central) - Oct 3, 2019
These data showed the early biological experience in Brazil that were associated with ADRs, withdrawals due to ADRs and SAEs. The quantification of adverse effects (serious or nonserious) considering close monitoring and patients' perceptions are increasingly important for future decision-making.
- | Humira (adalimumab) / Eisai, AbbVie
@abbvie @GSK_bio our med prices are so high, you wish you could afford medication when needed.#overpricedHumira (Twitter) - Oct 3, 2019
- | Humira (adalimumab) / Eisai, AbbVie
@abbvie we make Humira! Lots of luck trying to pay for it.#baselesspriceincreses#ptslivesinthebalance (Twitter) - Oct 3, 2019
- | Humira (adalimumab) / AbbVie
Enrollment open: Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease (clinicaltrials.gov) - Oct 2, 2019
P2, N=8, Recruiting, Sponsor: University of Michigan
The quantification of adverse effects (serious or nonserious) considering close monitoring and patients' perceptions are increasingly important for future decision-making. Not yet recruiting --> Recruiting
- | Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Short-term efficacy of adalimumab in a patient with pyrin-associated autoinflammation with neutrophilic dermatosis. (Pubmed Central) - Oct 2, 2019
Not yet recruiting --> Recruiting No abstract available
- | Journal, Video: English-language videos on YouTube as a source of information on self-administer subcutaneous anti-tumour necrosis factor agent injections. (Pubmed Central) - Oct 2, 2019
There are a substantial number of English-language YouTube videos, with high quality, and rich content and reliability that can be sources of information on proper technique of anti-TNF self-injections. Physicians should direct patients to the reliable resources of information and educate them in online resource assessment, thereby improving treatment outcomes.
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease. (Pubmed Central) - Oct 2, 2019
Physicians should direct patients to the reliable resources of information and educate them in online resource assessment, thereby improving treatment outcomes. While current treatment options seem effective in a proportion of patients with UC and CD, others require multiple lines of therapy, suggesting an unmet need for alternative treatments in UC and CD to achieve disease control.